Background And Aims: The purpose of the present study was to examine for factors related to tiredness, cross-sectionally at the age of 75 years, and factors related to subsequent onset of tiredness, from age 75 to 80 in a non-disabled community-living population.
Methods: The study is part of the prospective Nordic Research on Aging Study (NORA) on the 1914 cohort in Jyväskylä, Finland and Glostrup, Denmark. In total, 546 non-disabled older men and women participated in the cross-sectional study at age 75, and 299 persons without tiredness and disability at baseline took part in the follow-up study, from age 75 to 80. Tiredness was measured by a validated scale based on the following items: using the toilet, washing and dressing lower body, and cutting toenails. Independent variables were: social position measured by housing tenure and income, chronic diseases, use of medicine, pain, muscle strength, lung function, cognitive performance, depressive symptoms, life satisfaction and insomnia.
Results: Analyses of cross-sectional data showed that social position, number of comorbidities, muscle impairment, pain and depressive mood were independently associated with tiredness. Longitudinal analyses showed that onset of tiredness was significantly or marginally significantly influenced by use of more than three drugs, muscle impairment, pain and cognitive impairment.
Conclusions: The present study showed that tiredness in non-disabled older adults is a result of multiple potentially modifiable factors, which may be fully treated or at least alleviated, thus increasing the well-being of the individual, as well as potentially slowing the progression of disability.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/BF03325206 | DOI Listing |
World J Gastrointest Oncol
January 2025
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Background: Gallbladder cancer (GBC) is the most common and aggressive subtype of biliary tract cancer (BTC) and has a poor prognosis. A newly developed regimen of gemcitabine, cisplatin, and durvalumab shows promise for the treatment of advanced BTC. However, the efficacy of this treatment for GBC remains unclear.
View Article and Find Full Text PDFJ Immunother Precis Oncol
February 2025
TopAlliance Biosciences Inc. Rockville, MD, USA.
Introduction: This was the first phase 1 study conducted in the United States. It consisted of dose-escalation (part A) and multiple indication-specific cohort expansion (part B), investigating the safety and preliminary efficacy of toripalimab (anti-programmed cell death-1 inhibitor) in patients with advanced malignancies.
Methods: Patients with advanced malignancies that progressed after treatment with at least one prior line of standard systemic therapy, including the patients with advanced/recurrent cholangiocarcinoma (CCA), received toripalimab 240 mg every 3 weeks in part B.
Background: Malaria is the disease caused by intracellular parasites known as species and is mainly transmitted by blood sucking female mosquitoes. During pregnancy, malaria results in severe complications to the mother, the fetus and the newborn. Symptoms of malaria, such as fever, malaise, headache, nausea and vomiting, in pregnant women can be mistakenly attributed solely to pregnancy.
View Article and Find Full Text PDFNarra J
December 2024
Division of Psychosomatic and Palliative, Department of Internal Medicine, Faculty of Medicine, Universitas Udayana, Bali, Indonesia.
The incidence of psychosomatic disorders is increasing in Indonesia, and therefore screening instruments that are culturally appropriate for the Indonesian population are needed. The aim of this study was to assess the validity and reliability of the Shatri Sinulingga psychosomatic test (SSPT) questionnaire as a screening instrument for psychosomatic disorders in Indonesia. An analytic descriptive cross-sectional study divided into two stages (questionnaire formulation and distribution through the Psikosom.
View Article and Find Full Text PDFJ Gastrointest Oncol
December 2024
Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China.
Background: Regorafenib, approved in China for the third-line treatment of patients with metastatic colorectal cancer (mCRC), targets multiple tyrosine kinases. We retrospectively evaluated the efficacy and safety of regorafenib, both as monotherapy and in combination with capecitabine or immune checkpoint inhibitors (ICIs), as a second-line treatment for patients unable to access hospital-based care due to limited hospital visits during the coronavirus disease 2019 (COVID-19) pandemic.
Methods: Retrospective analysis was conducted on individual patient data from Peking University Third Hospital, covering the period from January 2020 to September 2023.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!